Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 2
1999 2
2000 3
2001 1
2002 3
2003 4
2004 3
2005 3
2006 6
2007 5
2008 7
2009 5
2010 4
2011 6
2012 4
2013 6
2014 7
2015 11
2016 10
2017 6
2018 6
2019 7
2020 8
2021 7
2022 9
Text availability
Article attribute
Article type
Publication date

Search Results

121 results
Results by year
Filters applied: . Clear all
Page 1
Clinical promise of next-generation complement therapeutics.
Mastellos DC, Ricklin D, Lambris JD. Mastellos DC, et al. Nat Rev Drug Discov. 2019 Sep;18(9):707-729. doi: 10.1038/s41573-019-0031-6. Epub 2019 Jul 19. Nat Rev Drug Discov. 2019. PMID: 31324874 Free PMC article. Review.
Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis.
Skendros P, Mitsios A, Chrysanthopoulou A, Mastellos DC, Metallidis S, Rafailidis P, Ntinopoulou M, Sertaridou E, Tsironidou V, Tsigalou C, Tektonidou M, Konstantinidis T, Papagoras C, Mitroulis I, Germanidis G, Lambris JD, Ritis K. Skendros P, et al. J Clin Invest. 2020 Nov 2;130(11):6151-6157. doi: 10.1172/JCI141374. J Clin Invest. 2020. PMID: 32759504 Free PMC article. Clinical Trial.
COVID-19 serum induced complement activation in vitro, consistent with high complement activity in clinical samples. Complement C3 inhibition with compstatin Cp40 disrupted TF expression in neutrophils. In conclusion, we provide a mechanistic basis for a pivotal role of co …
COVID-19 serum induced complement activation in vitro, consistent with high complement activity in clinical samples. Complement C3 inhibitio …
Innate immune responses to trauma.
Huber-Lang M, Lambris JD, Ward PA. Huber-Lang M, et al. Nat Immunol. 2018 Apr;19(4):327-341. doi: 10.1038/s41590-018-0064-8. Epub 2018 Mar 5. Nat Immunol. 2018. PMID: 29507356 Free PMC article. Review.
Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation.
Nilsson B, Larsson R, Hong J, Elgue G, Ekdahl KN, Sahu A, Lambris JD. Nilsson B, et al. Blood. 1998 Sep 1;92(5):1661-7. Blood. 1998. PMID: 9716594 Free article.
Compstatin effectively inhibited the generation of C3a and sC5b-9 and the binding of C3/ C3 fragments to the polymer surface. ...These data show that complement activation, leading to activation and binding of PMNs to the biomaterial surface, can be abolished by the additi
Compstatin effectively inhibited the generation of C3a and sC5b-9 and the binding of C3/ C3 fragments to the polymer surface. ...Thes
Thermodynamic studies on the interaction of the third complement component and its inhibitor, compstatin.
Katragadda M, Morikis D, Lambris JD. Katragadda M, et al. J Biol Chem. 2004 Dec 31;279(53):54987-95. doi: 10.1074/jbc.M409963200. Epub 2004 Oct 15. J Biol Chem. 2004. PMID: 15489226 Free article.
Compstatin is a 13-residue cyclic peptide that inhibits complement activation by binding to complement component, C3. ...In the present study, isothermal titration calorimetry was employed to dissect the molecular forces that govern the interaction of compstatin wit
Compstatin is a 13-residue cyclic peptide that inhibits complement activation by binding to complement component, C3. ...In the prese
Binding kinetics, structure-activity relationship, and biotransformation of the complement inhibitor compstatin.
Sahu A, Soulika AM, Morikis D, Spruce L, Moore WT, Lambris JD. Sahu A, et al. J Immunol. 2000 Sep 1;165(5):2491-9. doi: 10.4049/jimmunol.165.5.2491. J Immunol. 2000. PMID: 10946275 Free article.
Herein, we describe the binding kinetics, structure-activity relationship, and biotransformation of Compstatin. Biomolecular interaction analysis using surface-plasmon resonance showed that Compstatin bound to native C3 and its fragments C3b and C3c, but not C3d. Wh …
Herein, we describe the binding kinetics, structure-activity relationship, and biotransformation of Compstatin. Biomolecular interact …
Compstatins: the dawn of clinical C3-targeted complement inhibition.
Lamers C, Mastellos DC, Ricklin D, Lambris JD. Lamers C, et al. Trends Pharmacol Sci. 2022 Aug;43(8):629-640. doi: 10.1016/j.tips.2022.01.004. Epub 2022 Jan 25. Trends Pharmacol Sci. 2022. PMID: 35090732 Review.
Upstream intervention at the level of C3 activation has therefore been considered promising. The approval of pegcetacoplan, a C3 inhibitor of the compstatin family, in 2021 served as critical validation of C3-targeted treatment. This review delineates the evolution of the …
Upstream intervention at the level of C3 activation has therefore been considered promising. The approval of pegcetacoplan, a C3 inhibitor o …
Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitors.
Lamers C, Xue X, Smieško M, van Son H, Wagner B, Berger N, Sfyroera G, Gros P, Lambris JD, Ricklin D. Lamers C, et al. Nat Commun. 2022 Sep 20;13(1):5519. doi: 10.1038/s41467-022-33003-7. Nat Commun. 2022. PMID: 36127336 Free PMC article.
Moreover, compstatin derivatives with enhanced pharmacodynamic and pharmacokinetic profiles are in clinical development (e.g., Cp40/AMY-101). ...Our study may thereby guide the application of existing and development of next-generation compstatin analogs....
Moreover, compstatin derivatives with enhanced pharmacodynamic and pharmacokinetic profiles are in clinical development (e.g., Cp40/A …
Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primates.
Hughes S, Gumas J, Lee R, Rumano M, Berger N, Gautam AK, Sfyroera G, Chan AL, Gnanaguru G, Connor KM, Kim BJ, Dunaief JL, Ricklin D, Hajishengallis G, Yancopoulou D, Reis ES, Mastellos DC, Lambris JD. Hughes S, et al. Clin Immunol. 2020 May;214:108391. doi: 10.1016/j.clim.2020.108391. Epub 2020 Mar 27. Clin Immunol. 2020. PMID: 32229292 Free PMC article.
In this regard, a PEGylated second-generation derivative of the compstatin family of C3-targeted inhibitors is currently in late-stage clinical development as a treatment option for geographic atrophy, an advanced form of AMD which lacks approved therapy. ...Here we report …
In this regard, a PEGylated second-generation derivative of the compstatin family of C3-targeted inhibitors is currently in late-stag …
121 results